Angelini Pharma said on Thursday that it would acquire U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal, marking the Italian drugmaker’s entry into the U.S. pharmaceutical market. The...
Pharmaceutical
LEO Pharma to buy U.S. drug developer Replay for $50 million upfront
Danish drugmaker LEO Pharma said on Thursday it had agreed to buy U.S. drug developer Replay for $50 million upfront, adding an experimental treatment platform for rare genetic skin diseases to its dermatology...
Quadria, PE funds eye stake in Samarth Lifesciences; deal may value firm at Rs 4,500 crore
Quadria Capital is among 4-5 private equity investors evaluating a potential acquisition of a controlling 80-85% stake in Samarth Lifesciences, said people familiar with the matter. A deal could value the manufacturer...
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
Kashiv BioSciences, LLC (“Kashiv”), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”). The transaction is...
Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says
U.S. drugmaker Eli Lilly is in advanced talks to acquire biotech firm Kelonia Therapeutics for more than $2 billion, the Wall Street Journal reported on Sunday. A deal could be reached as soon as Monday and could...
Rubicon Research gains as acquire 85% stake in Arinna Lifesciences for Rs 176 crore
Rubicon Research rose 1.02% to Rs 879 after it has announced the acquisition of an 85% equity stake in Arinna Lifesciences, a branded pharmaceutical marketing company focused on the CNS and neuro-psychiatric segment in...
Everstone invests $270 million in Apothecon Group for a significant stake
Singapore-based private equity firm Everstone Capital will invest close to $270 million for a significant stake in Apothecon Group, which includes India-based Apothecon and US-based Navinta, it said in a statement on...
Sun Pharma closes in on Organon buy, gets set for $12 billion binding bid
Sun Pharmaceutical Industries has decided to proceed with a binding offer of $12 billion for Organon & Co, taking the company to the final stages of its most ambitious overseas acquisition bid as it looks to become...
IHH Healthcare aims to hike its stake in Fortis to 50%: CEO Prem Kumar Nair
Even as legal battles continue to simmer in the background, IHH Healthcare, one of Asia’s largest hospital groups, has identified India as a key growth market, with its sights firmly set on becoming one of the...
Gilead to buy Germany’s Tubulis for up to $5 billion to boost cancer pipeline
Gilead said on Tuesday it would acquire Germany-based Tubulis GmbH for up to $5 billion, as it looks to strengthen its cancer drugs pipeline. This marks the latest in Gilead’s acquisition spree. The company has...
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout
Neurocrine Biosciences will acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash, the companies said on Monday, marking the neuroscience-focused drugmaker’s expansion into metabolic...
Koye Pharma next on Warburg’s health play
Global private equity fund Warburg Pincus is in advanced discussions to acquire Mumbai-based Koye Pharma, a drugmaker that has built its presence across women’s health, respiratory care, and anti-diabetes drugs...
